VIENNA — Integrin inhibitor risuteganib was effective in complementing the anti-VEGF pathway when administered sequentially to an anti-VEGF drug in patients with diabetic macular edema, according to the results of the DEL MAR phase 2b trial.
“Positive results were driven by patients who responded poorly to anti-VEGF therapy, exactly the patients who need the most help,” Pravin Dugel, MD, said at the Euretina meeting.
Integrins are cell surface receptors that mediate cell-to-cell interaction with further downstream kinase signaling and are upregulated in times of oxidative
Uncategorized